{"id":"alum","rwe":[{"pmid":"41893753","year":"2026","title":"Investigating the In Vitro Immunomodulatory Potential of Microparticulate β-L-Adenosine in Particulate Vaccine Candidates.","finding":"","journal":"Vaccines","studyType":"Clinical Study"},{"pmid":"41887876","year":"2026","title":"Simultaneous removal of fluoride and disinfection by-product precursors through Zr salt enhanced coagulation.","finding":"","journal":"Journal of environmental sciences (China)","studyType":"Clinical Study"},{"pmid":"41886848","year":"2026","title":"Calcined oyster shell powder as a sustainable alternative to chemical coagulants for enhanced turbidity removal: Optimization of coagulation parameters.","finding":"","journal":"Journal of environmental management","studyType":"Clinical Study"},{"pmid":"41865485","year":"2026","title":"DNA electroporation of HIV Env elicits robust T cell responses and memory B cell responses with muted serum antibody levels that can be boosted with recombinant protein.","finding":"","journal":"Vaccine","studyType":"Clinical Study"},{"pmid":"41844084","year":"2026","title":"Two dimensional layered double hydroxides augment antigen loading and release.","finding":"","journal":"Biomaterials advances","studyType":"Clinical Study"}],"_fda":{"id":"46051d5f-d0ec-e853-e063-6294a90a4922","set_id":"12dea1d1-9510-5aad-e054-00144ff8d46c","openfda":{"nui":["N0000185375","N0000175629","N0000184306","N0000185001","M0000728","M0016962","M0516536"],"unii":["2P3VWU3H10","V5VD430YW9","IWY3IWX2G8","2E32821G6I","1L24V9R23S","269XH13919","M2O62YTN42"],"route":["ORAL"],"spl_id":["46051d5f-d0ec-e853-e063-6294a90a4922"],"brand_name":["Constipation Relief"],"spl_set_id":["12dea1d1-9510-5aad-e054-00144ff8d46c"],"package_ndc":["17312-031-14"],"product_ndc":["17312-031"],"generic_name":["ALOE, POTASSIUM ALUM, OYSTER SHELL CALCIUM CARBONATE, CRUDE ACTIVATED CHARCOAL, DIOSCOREA VILLOSA TUBER, VERONICASTRUM VIRGINICUM ROOT, STRYCHNOS NUX VOMICA SEED"],"product_type":["HUMAN OTC DRUG"],"pharm_class_cs":["Allergens [CS]","Plant Proteins [CS]","Seed Storage Proteins [CS]"],"pharm_class_pe":["Increased Histamine Release [PE]","Cell-mediated Immunity [PE]","Increased IgG Production [PE]"],"substance_name":["ACTIVATED CHARCOAL","ALOE","DIOSCOREA VILLOSA ROOT","OYSTER SHELL CALCIUM CARBONATE, CRUDE","POTASSIUM ALUM","STRYCHNOS NUX-VOMICA SEED","VERONICASTRUM VIRGINICUM ROOT"],"pharm_class_epc":["Non-Standardized Plant Allergenic Extract [EPC]"],"manufacturer_name":["TRP Company"],"is_original_packager":[true]},"purpose":["Aloe socotrina HPUS Flatulence, Bloating, Burning in rectum Alumen HPUS Hard, dry, difficult stools Calcarea carbonica HPUS Strained elimination, Greater if overweight Carbo vegetabilis HPUS Ineffective evacuation Dioscorea villosa HPUS Hemorrhoids Leptandra virginica HPUS Cramping in stomach and intestines Nux vomica HPUS Frequent ineffective urging, Constant uneasiness"],"version":"5","stop_use":["Stop Use Stop use and ask a doctor if: You experience worsening symptoms. If symptoms last longer than 7 days. You get abdominal swelling or bulging."],"warnings":["Warnings: USE ONLY AFTER DIAGNOSIS BY A PHYSICIAN AND UNDER THE SUPERVISION OF A PHYSICIAN. This product is intended to complement, not replace, standard medical treatment. Initial worsening of symptoms may occur. A physician should always be consulted to rule out serious causes."],"questions":["www.thereliefproducts.com, 1-888-969-6855"],"do_not_use":["Do not use if tamper evident seal is torn, broken or missing."],"effective_time":"20251215","active_ingredient":["Active Ingredients Aloe socotrina HPUS 6x 12x 18x Alumen HPUS 6x 12x 18x Calcarea carbonica HPUS 6x 12x 18x Carbo vegetabilis HPUS 6x 12x 18x Dioscorea villosa HPUS 6x 12x 18x Leptandra virginica HPUS 6x 12x 18x Nux vomica HPUS 6x 12x 18x HPUS indicates the active ingredients are in the Homeopathic Pharmacopoeia of the United States."],"inactive_ingredient":["Inactive Ingredients Advantol® 300, Lactose, Magnesium Stearate, Mannitol, Microcrystalline Cellulose."],"indications_and_usage":["Uses:* According to homeopathic indications these ingredients temporarily relieve symptoms such as: • difficult elimination • dry, hard stools • cramping • ineffectual urgings and evacuation • gas • bloating • hemorrhoids. * These statements are based upon traditional homeopathic practice. They have not been reviewed by the Food and Drug Administration."],"spl_unclassified_section":["There are no known contraindications. Active ingredients are micro-diluted in accordance with the Homeopathic Pharmacopoeia of the United States and are therefore non-toxic with no known side effects. Store in a cool dark location. Constipation Relief ™ Homeopathic Fast Dissolving Tablet are homeopathic dilutions: see www.thereliefproducts.com for details."],"dosage_and_administration":["Directions Suitable for adults and children 12 years and above. Dissolve entire tablet under tongue. Do not chew or swallow whole. Take 1 tablet 3 times a day or as directed by a physician. Use up to 6 times a day as needed. Take at least 10 minutes before or at least 10 minutes after eating or drinking. Children under the age of 12: consult a physician before use. Homeopathic remedies may not be effective for everyone."],"spl_product_data_elements":["Constipation Relief Aloe, Potassium Alum, Oyster Shell Calcium Carbonate, Crude Activated Charcoal, Dioscorea Villosa Tuber, Veronicastrum Virginicum Root, Strychnos Nux Vomica Seed MANNITOL SORBITOL CROSPOVIDONE CELLULOSE, MICROCRYSTALLINE COPOVIDONE SILICON DIOXIDE LACTOSE MAGNESIUM STEARATE DIOSCOREA VILLOSA ROOT DIOSCOREA VILLOSA ROOT ACTIVATED CHARCOAL ACTIVATED CHARCOAL OYSTER SHELL CALCIUM CARBONATE, CRUDE OYSTER SHELL CALCIUM CARBONATE, CRUDE POTASSIUM ALUM ALUMINUM HYDROXIDE ALOE ALOE STRYCHNOS NUX-VOMICA SEED STRYCHNOS NUX-VOMICA SEED VERONICASTRUM VIRGINICUM ROOT VERONICASTRUM VIRGINICUM ROOT TRP"],"pregnancy_or_breast_feeding":["If pregnant or breast-feeding, ask a health professional before use."],"keep_out_of_reach_of_children":["Keep out of reach of children Keep out of reach of children In case of overdose, get medical help or contact a Poison Control Center right away."],"package_label_principal_display_panel":["Label Box"]},"tags":[{"label":"alum","category":"class"},{"label":"Small Molecule","category":"modality"},{"label":"S01XA07","category":"atc"},{"label":"Topical","category":"route"},{"label":"Gel","category":"form"},{"label":"Spray","category":"form"},{"label":"Active","category":"status"},{"label":"Gastric Hypersecretory Conditions","category":"indication"},{"label":"Gastroesophageal reflux disease","category":"indication"},{"label":"Heartburn","category":"indication"},{"label":"Hiatal Hernia with Reflux Esophagitis","category":"indication"},{"label":"Indigestion","category":"indication"},{"label":"Peptic ulcer","category":"indication"},{"label":"Novartis Pharmaceuticals","category":"company"},{"label":"Adjuvants, Immunologic","category":"pharmacology"},{"label":"Immunologic Factors","category":"pharmacology"}],"phase":"marketed","safety":{"boxedWarnings":[],"safetySignals":[{"date":"","signal":"ACUTE KIDNEY INJURY","source":"FDA FAERS","actionTaken":"3 reports"},{"date":"","signal":"DRUG INEFFECTIVE","source":"FDA FAERS","actionTaken":"2 reports"},{"date":"","signal":"OFF LABEL USE","source":"FDA FAERS","actionTaken":"2 reports"},{"date":"","signal":"RENAL TUBULAR NECROSIS","source":"FDA FAERS","actionTaken":"2 reports"},{"date":"","signal":"ACUTE RESPIRATORY FAILURE","source":"FDA FAERS","actionTaken":"1 reports"},{"date":"","signal":"ADHESION","source":"FDA FAERS","actionTaken":"1 reports"},{"date":"","signal":"ANAL INCONTINENCE","source":"FDA FAERS","actionTaken":"1 reports"},{"date":"","signal":"ANXIETY","source":"FDA FAERS","actionTaken":"1 reports"},{"date":"","signal":"ATRIAL FIBRILLATION","source":"FDA FAERS","actionTaken":"1 reports"},{"date":"","signal":"BACK PAIN","source":"FDA FAERS","actionTaken":"1 reports"}],"commonSideEffects":[]},"trials":[],"aliases":["Alhydrogel","Aluminium hydroxide"],"company":"Novartis Pharmaceuticals","patents":[],"pricing":[],"_sources":{"trials":{"url":"https://clinicaltrials.gov/search?intr=Alum","method":"api_direct","source":"ClinicalTrials.gov","rawText":"","confidence":1,"sourceType":"ctgov","retrievedAt":"2026-04-20T01:59:51.600962+00:00"},"timeline":{"url":"https://en.wikipedia.org/wiki/Alum","method":"deterministic","source":"Wikipedia","rawText":"","confidence":0.8,"sourceType":"wikipedia","retrievedAt":"2026-04-20T01:59:59.764175+00:00"},"regulatory.ca":{"url":"","method":"api_direct","source":"Health Canada DPD","rawText":"","confidence":1,"sourceType":"health_canada_dpd","retrievedAt":"2026-04-20T01:59:58.379266+00:00"},"publicationCount":{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=Alum","method":"api_direct","source":"PubMed/NCBI","rawText":"","confidence":1,"sourceType":"pubmed","retrievedAt":"2026-04-20T01:59:59.149132+00:00"},"mechanism.drugClass":{"url":"https://api.fda.gov/drug/label.json","method":"deterministic","source":"FDA Label (EPC)","rawText":"","confidence":1,"sourceType":"fda_label","retrievedAt":"2026-04-20T01:59:49.372070+00:00"},"administration.route":{"url":"","method":"deterministic","source":"FDA Label","rawText":"","confidence":1,"sourceType":"fda_label","retrievedAt":"2026-04-20T01:59:49.372132+00:00"},"safety.boxedWarnings":{"url":"","method":"deterministic","source":"FDA Label (no boxed warning)","rawText":"","confidence":1,"sourceType":"fda_label","retrievedAt":"2026-04-20T01:59:49.372148+00:00"},"safety.safetySignals":{"url":"https://api.fda.gov/drug/event.json","method":"api_direct","source":"FDA FAERS","rawText":"","confidence":1,"sourceType":"fda_faers","retrievedAt":"2026-04-20T02:00:00.838147+00:00"},"crossReferences.chemblId":{"url":"https://www.ebi.ac.uk/chembl/compound_report_card/CHEMBL2107960/","method":"api_direct","source":"ChEMBL (EMBL-EBI)","rawText":"","confidence":1,"sourceType":"chembl","retrievedAt":"2026-04-20T01:59:59.647473+00:00"}},"allNames":"potassium alum","offLabel":[],"synonyms":["alum","aluminum potassium sulfate","alum potassium","potassium alum"],"timeline":[],"brandName":"Potassium Alum","ecosystem":[{"indication":"Gastric Hypersecretory Conditions","otherDrugs":[{"name":"algeldrate","slug":"algeldrate","company":"Sanofi Aventis Us"},{"name":"almasilate","slug":"almasilate","company":""},{"name":"lansoprazole","slug":"lansoprazole","company":"Takeda Pharms Usa"},{"name":"magnesium carbonate","slug":"magnesium-carbonate","company":"United Guardian"}],"globalPrevalence":null},{"indication":"Gastroesophageal reflux disease","otherDrugs":[{"name":"algeldrate","slug":"algeldrate","company":"Sanofi Aventis Us"},{"name":"almasilate","slug":"almasilate","company":""},{"name":"cimetidine","slug":"cimetidine","company":""},{"name":"cisapride","slug":"cisapride","company":""}],"globalPrevalence":null},{"indication":"Heartburn","otherDrugs":[{"name":"algeldrate","slug":"algeldrate","company":"Sanofi Aventis Us"},{"name":"almasilate","slug":"almasilate","company":""},{"name":"cimetidine","slug":"cimetidine","company":""},{"name":"famotidine","slug":"famotidine","company":"Valeant Pharms North"}],"globalPrevalence":320000000},{"indication":"Hiatal Hernia with Reflux Esophagitis","otherDrugs":[{"name":"almasilate","slug":"almasilate","company":""},{"name":"magnesium carbonate","slug":"magnesium-carbonate","company":"United Guardian"},{"name":"magnesium hydroxide","slug":"magnesium-hydroxide","company":"Mcneil Cons"},{"name":"magnesium silicate","slug":"magnesium-silicate","company":"Sanofi Aventis Us"}],"globalPrevalence":null},{"indication":"Indigestion","otherDrugs":[{"name":"algeldrate","slug":"algeldrate","company":"Sanofi Aventis Us"},{"name":"almasilate","slug":"almasilate","company":""},{"name":"bismuth subsalicylate","slug":"bismuth-subsalicylate","company":"Prometheus Labs"},{"name":"calcium carbonate","slug":"calcium-carbonate","company":"Mcneil Cons"}],"globalPrevalence":null},{"indication":"Peptic ulcer","otherDrugs":[{"name":"algeldrate","slug":"algeldrate","company":"Sanofi Aventis Us"},{"name":"almasilate","slug":"almasilate","company":""},{"name":"chlordiazepoxide","slug":"chlordiazepoxide","company":"Valeant Pharm Intl"},{"name":"dexlansoprazole","slug":"dexlansoprazole","company":"Takeda Pharms Usa"}],"globalPrevalence":64000000}],"mechanism":{"modality":"Small Molecule","drugClass":"Non-Standardized Plant Allergenic Extract [EPC]","explanation":"","oneSentence":"","technicalDetail":"Alum acts as an acid-binding agent, forming a complex with hydrochloric acid and other gastric acids, thereby reducing the concentration of free hydrogen ions and alleviating symptoms of gastric hypersecretory conditions."},"_wikipedia":{"url":"https://en.wikipedia.org/wiki/Alum","title":"Alum","extract":"An alum is a type of chemical compound, usually a hydrated double sulfate salt of aluminium with the general formula XAl(SO4)2·12H2O, such that X is a monovalent cation such as potassium or ammonium. By itself, alum often refers to potassium alum, with the formula KAl(SO4)2·12H2O. Other alums are named after the monovalent ion, such as sodium alum and ammonium alum.","wiki_history":"==History==\n\n===Alum found at archaeological sites===\nThe western desert of Egypt was a major source of alum substitutes in antiquity. These evaporites were mainly , , , , and . \n}}  The Ancient Greek Herodotus mentions Egyptian alum as a valuable commodity in his Histories.\n\nThe production of potassium alum from alunite is archaeologically attested on the island Lesbos.\n\n}} The site was abandoned during the 7th&nbsp;century&nbsp;CE, but dates back at least to the 2nd&nbsp;century&nbsp;CE. Native alumen from the island of Melos appears to have been a mixture mainly of alunogen () with potassium alum and other minor sulfates.\n\n}}\n\n===Alumen in Pliny and Dioscorides===\nA detailed description of a substance termed alumen occurs in the Roman Pliny the Elder's Natural History.\n\nBy comparing Pliny's description with the account of stypteria (στυπτηρία) given by Dioscorides, it is obvious the two are identical. Pliny informs us that a form of alumen was found naturally in the earth, and terms it salsugoterrae.\n\nPliny wrote that different substances were distinguished by the name of alumen, but they were all characterised by a certain degree of astringency, and were all employed for dyeing and medicine. Pliny wrote that there is another kind of alum that the ancient Greeks term schiston, and which \"splits into filaments of a whitish colour\". From the name schiston and the mode of formation, it seems that this kind was the salt that forms spontaneously on certain salty minerals, as alum slate and bituminous shale, and consists mainly of sulfates of iron and aluminium. One kind of alumen was a liquid, which was apt to be adulterated; but when pure it had the property of blackening when added to pomegranate juice. This property seems to characterize a solution of iron sulfate in water; a solution of ordinary (potassium) alum would possess no such property. Contamination with iron sulfate was greatly disliked as this darkened and dulled dye colours. In some places the iron sulf"},"commercial":{},"references":[{"id":1,"url":"https://drugcentral.org/drugcard/4325","fields":["approvals","synonyms","ATC","PK","indications","contraindications","DDIs","targets","patents","FAERS"],"source":"DrugCentral"},{"id":2,"url":"https://clinicaltrials.gov/search?intr=Alum","fields":["trials"],"source":"ClinicalTrials.gov"},{"id":3,"url":"https://pubmed.ncbi.nlm.nih.gov/?term=Alum","fields":["publications"],"source":"PubMed/NCBI"},{"id":4,"url":"https://en.wikipedia.org/wiki/Alum","fields":["history","overview"],"source":"Wikipedia"}],"_enrichedAt":"2026-03-30T08:39:06.186451","_validation":{"fieldsValidated":0,"lastValidatedAt":"2026-04-20T02:00:02.611326+00:00","fieldsConflicting":1,"overallConfidence":0.8},"biosimilars":[],"competitors":[{"drugName":"retinol","drugSlug":"retinol","fdaApproval":"1953-02-20","relationship":"same-class"},{"drugName":"sodium chloride","drugSlug":"sodium-chloride","fdaApproval":"1965-12-16","genericCount":11,"patentStatus":"Off-patent — generic available","relationship":"same-class"},{"drugName":"potassium iodide","drugSlug":"potassium-iodide","fdaApproval":"1979-11-09","genericCount":3,"patentStatus":"Off-patent — generic available","relationship":"same-class"},{"drugName":"acetylcysteine","drugSlug":"acetylcysteine","fdaApproval":"1963-09-14","patentExpiry":"May 8, 2032","patentStatus":"Patent protected","relationship":"same-class"},{"drugName":"inosine","drugSlug":"inosine","fdaApproval":"","relationship":"same-class"},{"drugName":"dexpanthenol","drugSlug":"dexpanthenol","fdaApproval":"1953-02-20","relationship":"same-class"},{"drugName":"alteplase","drugSlug":"alteplase","fdaApproval":"1996-06-18","relationship":"same-class"},{"drugName":"heparin","drugSlug":"heparin","fdaApproval":"1939-02-09","patentStatus":"Unknown","relationship":"same-class"},{"drugName":"ascorbic acid","drugSlug":"ascorbic-acid","fdaApproval":"","genericCount":1,"patentStatus":"Off-patent — generic available","relationship":"same-class"},{"drugName":"ciclosporin","drugSlug":"ciclosporin","fdaApproval":"1983-11-14","relationship":"same-class"},{"drugName":"mercaptamine","drugSlug":"mercaptamine","fdaApproval":"1994-08-15","relationship":"same-class"},{"drugName":"ocriplasmin","drugSlug":"ocriplasmin","fdaApproval":"2012-10-17","relationship":"same-class"},{"drugName":"sirolimus","drugSlug":"sirolimus","fdaApproval":"1999-09-15","patentExpiry":"Oct 28, 2040","patentStatus":"Patent protected","relationship":"same-class"},{"drugName":"lifitegrast","drugSlug":"lifitegrast","fdaApproval":"2016-07-11","patentExpiry":"Oct 21, 2030","patentStatus":"Patent protected","relationship":"same-class"},{"drugName":"riboflavin","drugSlug":"riboflavin","fdaApproval":"1953-02-20","patentStatus":"Unknown","relationship":"same-class"},{"drugName":"varenicline","drugSlug":"varenicline","fdaApproval":"2006-05-10","patentExpiry":"Oct 19, 2035","patentStatus":"Patent protected","relationship":"same-class"}],"genericName":"alum","indications":{"approved":[{"name":"Gastric Hypersecretory Conditions","source":"DrugCentral","snomedId":"","regulator":"FDA","eligibility":"Adults with Zollinger-Ellison syndrome or other gastric hypersecretory conditions"},{"name":"Gastroesophageal reflux disease","source":"DrugCentral","snomedId":235595009,"regulator":"FDA","eligibility":"Adults with symptoms of acid reflux"},{"name":"Heartburn","source":"DrugCentral","snomedId":16331000,"regulator":"FDA","eligibility":"Adults with symptoms of heartburn","usPrevalence":null,"globalPrevalence":320000000,"prevalenceMethod":"curated","prevalenceSource":"BMC Pregnancy Childbirth, 2025 (PMID:41366751)"},{"name":"Hiatal Hernia with Reflux Esophagitis","source":"DrugCentral","snomedId":"","regulator":"FDA","eligibility":"Adults with hiatal hernia and symptoms of acid reflux"},{"name":"Indigestion","source":"DrugCentral","snomedId":162031009,"regulator":"FDA","eligibility":"Adults with symptoms of indigestion"},{"name":"Peptic ulcer","source":"DrugCentral","snomedId":13200003,"regulator":"FDA","eligibility":"Adults with active duodenal ulcers or gastric ulcers","usPrevalence":null,"globalPrevalence":64000000,"prevalenceMethod":"curated","prevalenceSource":"Aliment Pharmacol Ther, 2009 (PMID:19220208)"}],"offLabel":[{"name":"Multiple endocrine adenomas","source":"DrugCentral","drugName":"Alum","evidenceCount":0,"evidenceLevel":"emerging"},{"name":"Stress-Related GI Mucosal Bleeding Prevention","source":"DrugCentral","drugName":"Alum","evidenceCount":0,"evidenceLevel":"emerging"},{"name":"Systemic mast cell disease","source":"DrugCentral","drugName":"Alum"}],"pipeline":[]},"drugCategory":"active","labelChanges":[],"relatedDrugs":[{"drugId":"retinol","brandName":"retinol","genericName":"retinol","approvalYear":"1953","relationship":"same-class"},{"drugId":"sodium-chloride","brandName":"sodium chloride","genericName":"sodium chloride","approvalYear":"1965","relationship":"same-class"},{"drugId":"potassium-iodide","brandName":"potassium iodide","genericName":"potassium iodide","approvalYear":"1979","relationship":"same-class"},{"drugId":"acetylcysteine","brandName":"acetylcysteine","genericName":"acetylcysteine","approvalYear":"1963","relationship":"same-class"},{"drugId":"inosine","brandName":"inosine","genericName":"inosine","approvalYear":"","relationship":"same-class"},{"drugId":"dexpanthenol","brandName":"dexpanthenol","genericName":"dexpanthenol","approvalYear":"1953","relationship":"same-class"},{"drugId":"alteplase","brandName":"alteplase","genericName":"alteplase","approvalYear":"1996","relationship":"same-class"},{"drugId":"heparin","brandName":"heparin","genericName":"heparin","approvalYear":"1939","relationship":"same-class"},{"drugId":"ascorbic-acid","brandName":"ascorbic acid","genericName":"ascorbic acid","approvalYear":"","relationship":"same-class"},{"drugId":"ciclosporin","brandName":"ciclosporin","genericName":"ciclosporin","approvalYear":"1983","relationship":"same-class"}],"trialDetails":[{"nctId":"NCT06680479","phase":"PHASE1","title":"Safety and Immunogenicity of Stabilized CH505 TF chTrimer Vaccination in Adults Living With HIV-1 on Suppressive Antiretroviral Therapy","status":"SUSPENDED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2025-04-01","conditions":["HIV-1"],"enrollment":30,"completionDate":"2028-04-14"},{"nctId":"NCT04915768","phase":"PHASE1","title":"Evaluating the Safety and Immunogenicity of Stabilized CH505 TF chTrimer in Healthy, HIV-uninfected Adult Participants.","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2023-01-23","conditions":["HIV Infections"],"enrollment":51,"completionDate":"2025-07-15"},{"nctId":"NCT05018585","phase":"PHASE3","title":"A Phase III Study to Investigate if the Study Drug Diamyd Can Preserve Insulin Production and Improve Glycemic Control in Patients Newly Diagnosed With Type 1 Diabetes","status":"ACTIVE_NOT_RECRUITING","sponsor":"Diamyd Medical AB","startDate":"2022-05-19","conditions":["Type 1 Diabetes Mellitus"],"enrollment":330,"completionDate":"2027-12"},{"nctId":"NCT07408297","phase":"PHASE2","title":"Evaluating Safety and Immune Response of Janssen, Moderna, Pfizer/BNT, and Novavax COVID-19 Vaccines for Same and Mixed Boosters in Adolescents and Adults Aged 12-64 With and Without HIV in Kenya, DRC, and Rwanda","status":"COMPLETED","sponsor":"Victoria Biomedical Research Institute","startDate":"2022-05-18","conditions":["COVID -19","SARS CoV 2 Infection"],"enrollment":1919,"completionDate":"2024-06-27"},{"nctId":"NCT05471076","phase":"PHASE1","title":"Trial to Evaluate the Safety and Immunogenicity of Priming Regimens of 426c.Mod.Core-C4b and Optional Boost Regimen With HIV Trimer BG505 SOSIP.GT1.1 gp140, Both Adjuvanted With 3M-052-AF + Alum in Healthy, Adult Participants Without HIV","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2022-08-22","conditions":["HIV-1-infection"],"enrollment":52,"completionDate":"2026-05-21"},{"nctId":"NCT04985760","phase":"PHASE1","title":"Evaluation of Trimer 4571 Therapeutic Vaccination in Adults Living With HIV on Suppressive Antiretroviral Therapy","status":"COMPLETED","sponsor":"Madhu Chhanda Choudhary","startDate":"2021-09-30","conditions":["HIV Infections"],"enrollment":32,"completionDate":"2026-01-16"},{"nctId":"NCT05561673","phase":"PHASE1","title":"A Study on the Safety and Immune Response of AS37 Together With Hepatitis B Antigen in Adults Aged 18-45 Years","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2022-10-04","conditions":["Hepatitis B"],"enrollment":122,"completionDate":"2024-11-29"},{"nctId":"NCT05903339","phase":"PHASE1","title":"Clinical Trial to Evaluate the Safety and Immunogenicity of Ferritin Nanoparticles Expressing Native-like HIV-1 Envelope Trimers Followed by Boost With mRNA Lipid Nanoparticles Encoding a Native-like HIV-1 Envelope Trimer in Adults Without HIV","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2023-08-29","conditions":["Hiv"],"enrollment":36,"completionDate":"2026-10-30"},{"nctId":"NCT06006546","phase":"PHASE1","title":"The Study of Immunization in People Living With HIV Undergoing an ATI for Elicitation of VRC01-lineage Antibodies","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2024-01-03","conditions":["Chronic HIV Infection"],"enrollment":35,"completionDate":"2026-10-27"},{"nctId":"NCT03878121","phase":"PHASE1","title":"Safety and Immunogenicity of Ad4-HIV Envelope Vaccine Vectors in Healthy Volunteers","status":"RECRUITING","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2019-04-17","conditions":["Healthy Volunteer"],"enrollment":300,"completionDate":"2026-10-15"},{"nctId":"NCT06613789","phase":"PHASE1","title":"Safety & Immunogenicity of 426c.Mod.Core-C4b Vaccine With 3M-052-AF+Alum in Infants Perinatally Exposed to HIV But Uninfected","status":"NOT_YET_RECRUITING","sponsor":"HIV Vaccine Trials Network","startDate":"2026-07-13","conditions":["HIV Infections"],"enrollment":22,"completionDate":"2027-06-03"},{"nctId":"NCT05781542","phase":"PHASE1","title":"Clinical Trial to Evaluate the Safety and Immunogenicity of Synthetic DNAs Encoding NP-GT8 and IL-12, With or Without a TLR-agonist-Adjuvanted HIV Env Trimer 4571 Boost, in Adults Without HIV","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2023-04-10","conditions":["HIV Infections"],"enrollment":46,"completionDate":"2025-04-14"},{"nctId":"NCT07195929","phase":"NA","title":"Determination of Blomia Tropicalis Allergen Extract in Prick Test Units","status":"NOT_YET_RECRUITING","sponsor":"Inmunotek S.L.","startDate":"2025-11","conditions":["Allergic Reactions","Allergic Skin Reaction"],"enrollment":30,"completionDate":"2027-01"},{"nctId":"NCT06796686","phase":"PHASE1","title":"Clinical Trial to Evaluate the Safety and Immunogenicity of a Priming Regimen of 426c.Mod.Core-C4b Followed by HxB2.WT.Core-C4b Boosts, Both Adjuvanted With 3M-052 AF + Alum, in Adult Participants Without HIV and in Overall Good Health","status":"RECRUITING","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2025-03-17","conditions":["HIV"],"enrollment":42,"completionDate":"2027-01-15"},{"nctId":"NCT03038802","phase":"PHASE1,PHASE2","title":"A Randomised Controlled Phase 1 Study of Vaccine Therapy for Control or Cure of Chronic Hepatitis B Virus Infection","status":"NOT_YET_RECRUITING","sponsor":"Vaxine Pty Ltd","startDate":"2026-03-01","conditions":["Chronic Hepatitis b"],"enrollment":40,"completionDate":"2027-06-30"},{"nctId":"NCT06905275","phase":"PHASE1","title":"A Clinical Trial to Evaluate the Safety and Immunogenicity of Glycan-trimmed HIV-1 Nanoparticle Vaccine (UVAX-1107), Followed by Homologous or Wild-type HIV-1 Nanoparticle Vaccine (UVAX-1197) Boost, Each Adjuvanted With 3M-052-AF + Alum in Adult Participants Without HIV","status":"SUSPENDED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2025-07-07","conditions":["HIV-1-infection"],"enrollment":25,"completionDate":"2027-07-20"},{"nctId":"NCT05828095","phase":"PHASE1","title":"A Clinical Trial to Evaluate the Safety and Immunogenicity of Synthetic DNAs Encoding a Native-like HIV Env Trimer and Interleukin-12 (INO-6160), Alone or in a Prime-boost Regimen With 3M-052-AF + Alum Adjuvanted VRC HIV Env Trimer 4571 in Adult Participants Without HIV","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2023-04-05","conditions":["HIV-1-infection"],"enrollment":20,"completionDate":"2025-01-23"},{"nctId":"NCT04177355","phase":"PHASE1","title":"Evaluating the Safety and Immunogenicity of HIV-1 BG505 SOSIP.664 gp140 With TLR Agonist and/or Alum Adjuvants in Healthy, HIV-uninfected Adults","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2020-01-13","conditions":["HIV Infections"],"enrollment":127,"completionDate":"2024-11-04"},{"nctId":"NCT07085702","phase":"PHASE1","title":"A Study to Evaluate Safety, Reactogenicity, and Immunogenicity of the GSK 4-component Strep A Vaccine With Aluminum Hydroxide (Alum) or AS37 in Healthy Young Adults","status":"RECRUITING","sponsor":"GlaxoSmithKline","startDate":"2025-07-31","conditions":["Streptococcal Infections"],"enrollment":108,"completionDate":"2026-11-30"},{"nctId":"NCT02952833","phase":"PHASE1","title":"ZIKA Vaccine in Naive Subjects","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2016-10-14","conditions":["Zika Virus Infection"],"enrollment":91,"completionDate":"2018-12-05"},{"nctId":"NCT04193189","phase":"PHASE3","title":"B-Enhancement of HBV Vaccination in Persons Living With HIV (BEe-HIVe): Evaluation of HEPLISAV-B","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2020-12-14","conditions":["HIV Infection","Hepatitis B"],"enrollment":638,"completionDate":"2024-08-13"},{"nctId":"NCT04262479","phase":"PHASE2","title":"Injections of Glutamic Acid Decarboxylase (GAD) for LADA Type of Diabetes","status":"COMPLETED","sponsor":"Norwegian University of Science and Technology","startDate":"2020-03-02","conditions":["Latent Autoimmune Diabetes in Adults"],"enrollment":14,"completionDate":"2022-05-05"},{"nctId":"NCT06194318","phase":"PHASE1","title":"First-in-human Safety and Immunogenicity Study of SCB-1019 and SCB-1019T in Healthy Adults","status":"COMPLETED","sponsor":"Clover Biopharmaceuticals AUS Pty","startDate":"2023-12-13","conditions":["Respiratory Syncytial Virus Vaccination"],"enrollment":160,"completionDate":"2025-05-07"},{"nctId":"NCT03295318","phase":"PHASE2","title":"Clinical Study of Meningococcal ACYWX Conjugate Vaccine, in 12-16 Month Olds","status":"COMPLETED","sponsor":"Serum Institute of India Pvt. Ltd.","startDate":"2017-11-15","conditions":["Meningitis, Meningococcal"],"enrollment":375,"completionDate":"2018-08-31"},{"nctId":"NCT06960278","phase":"EARLY_PHASE1","title":"Effect of Alum Stone Containing Mucosal Adhesive Patches on Healing of Recurrent Aphthous Stomatitis","status":"COMPLETED","sponsor":"University Of Anbar","startDate":"2021-02-05","conditions":["Aphthous Stomatitis, Recurrent","Aphthous Stomatitis","Aphthous Ulcer"],"enrollment":100,"completionDate":"2023-03-02"},{"nctId":"NCT05532566","phase":"NA","title":"Quercus Ilex and Quercus Robur Allergen Extracts Standardisation","status":"RECRUITING","sponsor":"Inmunotek S.L.","startDate":"2023-01-24","conditions":["Allergic Reaction","Allergic Skin Reaction","Allergy Pollen"],"enrollment":30,"completionDate":"2025-11-30"},{"nctId":"NCT06465420","phase":"PHASE1","title":"A Study to Evaluate Safety and Immunogenicity of Haemophilus Influenzae Serotype A Vaccine","status":"ACTIVE_NOT_RECRUITING","sponsor":"InventVacc Biologicals Inc.","startDate":"2024-05-29","conditions":["Haemophilus Influenzae Meningitis","Invasive Haemophilus Influenzae Disease"],"enrollment":30,"completionDate":"2025-09-15"},{"nctId":"NCT06267872","phase":"PHASE1","title":"A Clinical Trial in Adult Participants Without HIV and in Overall Good Health to Evaluate the Safety and Immunogenicity of CD4BS CH505M5 Pr-NP1 Followed by CH505 TF chTrimer Boost Both Adjuvanted With Either Lipid Nanoparticles (LNPs) or 3M-052-AF + Alum","status":"WITHDRAWN","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2024-10-07","conditions":["HIV"],"enrollment":0,"completionDate":"2026-09-12"},{"nctId":"NCT05613205","phase":"PHASE1","title":"Safety and Immunogenicity of a Novel Conjugate Vaccine Against Salmonella Typhi and Salmonella Paratyphi A in Healthy Adults","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2022-11-28","conditions":["Typhoid Fever"],"enrollment":97,"completionDate":"2024-04-02"},{"nctId":"NCT06332339","phase":"PHASE1","title":"Clinical Trial to Evaluate the Safety, Tolerability, and Immunogenicity of 16055 NFL Delta Gly4 Env Protein Trimer and Trimer 4571 Combined With 3M-052-AF + Alum Adjuvant and Ad4-Env145NFL Viral Particles as Heterologous Prime-boost Regimens in Adult Participants Without HIV.","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2024-03-15","conditions":["HIV"],"enrollment":45,"completionDate":"2026-11-11"},{"nctId":"NCT03992872","phase":"PHASE2","title":"Phase 2 Open-label Study of Alum-adjuvanted Chikungunya Virus-like Particle Vaccine (PXVX0317)","status":"COMPLETED","sponsor":"Bavarian Nordic","startDate":"2019-11-20","conditions":["Chikungunya"],"enrollment":60,"completionDate":"2021-01-19"},{"nctId":"NCT03755427","phase":"PHASE2","title":"A Study of An Adjuvanted Inactivated H7N9 Influenza Vaccine","status":"COMPLETED","sponsor":"Shanghai Institute Of Biological Products","startDate":"2018-11-10","conditions":["H7N9 Influenza"],"enrollment":560,"completionDate":"2019-11-15"},{"nctId":"NCT03369808","phase":"PHASE1,PHASE2","title":"A Clinical Trail Of An Adjuvanted Inactivated H7N9 Influenza Vaccine","status":"COMPLETED","sponsor":"Shanghai Institute Of Biological Products","startDate":"2017-12-29","conditions":["H7N9 Influenza"],"enrollment":360,"completionDate":"2019-11-15"},{"nctId":"NCT05533385","phase":"NA","title":"Juniperus Oxycedrus and Cupressus Arizonica Allergen Extracts Standardisation.","status":"COMPLETED","sponsor":"Inmunotek S.L.","startDate":"2023-10-10","conditions":["Allergy Pollen","Allergic Reaction","Allergic Skin Reaction"],"enrollment":30,"completionDate":"2024-01-22"},{"nctId":"NCT03284710","phase":"PHASE1,PHASE2","title":"Safety and Immunogenicity of Clade C ALVAC and gp120 HIV Vaccine","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2017-06-19","conditions":["HIV Infections"],"enrollment":132,"completionDate":"2019-12-12"},{"nctId":"NCT04524949","phase":"PHASE2","title":"IMCY-0098 Proof of ACtion in Type 1 Diabetes (IMPACT Study)","status":"TERMINATED","sponsor":"Imcyse SA","startDate":"2020-12-29","conditions":["Diabetes Mellitus, Type 1"],"enrollment":110,"completionDate":"2024-05-29"},{"nctId":"NCT05983874","phase":"PHASE1","title":"A Study to Evaluate the Safety and Immunogenicity of 2 Doses of 100µg BG505 SOSIP.664 gp140 Vaccine, Adjuvanted, Given to a Population of Adults Who Have Received 3 Doses of 300µg BG505 SOSIP.GT1.1 gp140 Vaccine, Adjuvanted","status":"ENROLLING_BY_INVITATION","sponsor":"International AIDS Vaccine Initiative","startDate":"2024-04-16","conditions":["Hiv"],"enrollment":8,"completionDate":"2025-03"},{"nctId":"NCT00135629","phase":"PHASE3","title":"Factors Predicting Efficacy of Allergen Injection Immunotherapy for Grass Pollen Hayfever","status":"COMPLETED","sponsor":"Imperial College London","startDate":"2002-10","conditions":["Rhinitis, Allergic, Seasonal"],"enrollment":18,"completionDate":"2008-10"},{"nctId":"NCT02963909","phase":"PHASE1","title":"A Phase 1, First-in-human, Double-blinded, Randomized, Placebo-controlled Trial of a Zika Virus Purified Inactivated Vaccine (ZPIV) With Alum Adjuvant in Healthy Flavivirus-naive and Flavivirus-Primed Subjects.","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2016-11-01","conditions":["Zika Virus Infection"],"enrollment":75,"completionDate":"2018-10-30"},{"nctId":"NCT02690181","phase":"PHASE2","title":"Extension Study to Evaluate the Immunogenicity and Safety of the Second Dose of GBS Trivalent Vaccine in Healthy Non-Pregnant Subjects.","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2016-03-29","conditions":["Bacterial Infection Due to Streptococcus, Group B","Streptococcus Agalactiae"],"enrollment":80,"completionDate":"2016-11-02"},{"nctId":"NCT05417269","phase":"PHASE1,PHASE2","title":"IMCY-0141 Safety and Efficacy in Multiple Sclerosis - ISEMIS Study","status":"ACTIVE_NOT_RECRUITING","sponsor":"Imcyse SA","startDate":"2022-04-12","conditions":["Multiple Sclerosis, Relapsing-Remitting"],"enrollment":150,"completionDate":"2025-12-31"},{"nctId":"NCT05752201","phase":"PHASE2,PHASE3","title":"ARVAC-A New Recombinant Coronavirus Disease 2019 (COVID-19) Vaccine","status":"COMPLETED","sponsor":"Centro de Educación Medica e Investigaciones Clínicas Norberto Quirno","startDate":"2023-02-06","conditions":["COVID-19 Vaccine"],"enrollment":2014,"completionDate":"2023-12-07"},{"nctId":"NCT05351879","phase":"PHASE1,PHASE2","title":"Evaluation of a Booster Administration of GAD-alum (Diamyd®) in Individuals With Type 1 Diabetes","status":"COMPLETED","sponsor":"Linkoeping University","startDate":"2022-05-09","conditions":["Diabetes Mellitus, Type 1"],"enrollment":6,"completionDate":"2023-08-29"},{"nctId":"NCT05433285","phase":"PHASE3","title":"Immuno-bridging Study of COVID-19 Protein Subunit Recombinant Vaccine","status":"COMPLETED","sponsor":"PT Bio Farma","startDate":"2022-06-07","conditions":["COVID-19"],"enrollment":4050,"completionDate":"2023-08-31"},{"nctId":"NCT03483961","phase":"PHASE2","title":"Trial of a Chikungunya Vaccine, PXVX0317 CHIKV-VLP, in Healthy Adults","status":"COMPLETED","sponsor":"Bavarian Nordic","startDate":"2018-04-18","conditions":["Chikungunya Virus Infection"],"enrollment":445,"completionDate":"2020-09-21"},{"nctId":"NCT05228314","phase":"PHASE1","title":"Safety and Immunogenicity Dose-finding Study of Adjuvanted SCB-2020S Vaccine in Adults","status":"COMPLETED","sponsor":"Clover Biopharmaceuticals AUS Pty","startDate":"2022-05-30","conditions":["COVID-19"],"enrollment":153,"completionDate":"2023-04-23"},{"nctId":"NCT05065983","phase":"PHASE2","title":"A Study to Assess the Safety and Immunogenicity of PXVX0317 Chikungunya Virus Virus-Like Particle Vaccine","status":"COMPLETED","sponsor":"Bavarian Nordic","startDate":"2021-10-11","conditions":["Chikungunya Virus"],"enrollment":25,"completionDate":"2022-05-05"},{"nctId":"NCT04672395","phase":"PHASE2,PHASE3","title":"A Controlled Phase 2/3 Study of Adjuvanted Recombinant SARS-CoV-2 Trimeric S-protein Vaccine (SCB-2019) for the Prevention of COVID-19","status":"COMPLETED","sponsor":"Clover Biopharmaceuticals AUS Pty","startDate":"2021-03-24","conditions":["COVID-19"],"enrollment":31454,"completionDate":"2023-04-23"},{"nctId":"NCT05863585","phase":"PHASE1","title":"A Clinical Trial to Evaluate the Safety and Immunogenicity of a Prophylactic HIV Vaccine Candidate","status":"UNKNOWN","sponsor":"International AIDS Vaccine Initiative","startDate":"2023-06","conditions":["Hiv"],"enrollment":14,"completionDate":"2025-03"},{"nctId":"NCT03970733","phase":"PHASE2","title":"Alternative Schedule Study For VLA15, a Vaccine Candidate Against Lyme Borreliosis","status":"COMPLETED","sponsor":"Pfizer","startDate":"2019-07-01","conditions":["Lyme Borreliosis"],"enrollment":246,"completionDate":"2022-03-28"},{"nctId":"NCT04982068","phase":"PHASE1","title":"Phase I Clinical Trial of Recombinant SARS-CoV-2 Spike Protein Vaccine (CHO Cell) for the Prevention of COVID-19","status":"UNKNOWN","sponsor":"Shanghai Zerun Biotechnology Co.,Ltd","startDate":"2021-07-12","conditions":["COVID-19"],"enrollment":72,"completionDate":"2023-06"},{"nctId":"NCT04990544","phase":"PHASE2","title":"Phase II Clinical Trial of Recombinant SARS-CoV-2 Spike Protein Vaccine (CHO Cell) for the Prevention of COVID-19","status":"UNKNOWN","sponsor":"Shanghai Zerun Biotechnology Co.,Ltd","startDate":"2021-07-31","conditions":["COVID-19"],"enrollment":528,"completionDate":"2023-11"},{"nctId":"NCT04742738","phase":"PHASE1,PHASE2","title":"Safety and Immunogenicity Study of SARS-CoV-2 Nanoparticle Vaccine (GBP510) Adjuvanted With Aluminum Hydroxide (COVID-19)","status":"COMPLETED","sponsor":"SK Bioscience Co., Ltd.","startDate":"2021-01-20","conditions":["COVID-19 (Healthy Volunteers)"],"enrollment":260,"completionDate":"2022-07-07"},{"nctId":"NCT04760743","phase":"PHASE1","title":"Safety and Immunogenicity of a SARS-CoV-2 Vaccine (NBP2001) in Healthy Adults (COVID-19)","status":"COMPLETED","sponsor":"SK Bioscience Co., Ltd.","startDate":"2020-12-17","conditions":["COVID-19 (Healthy Volunteers)"],"enrollment":50,"completionDate":"2022-03-02"},{"nctId":"NCT05313035","phase":"PHASE2,PHASE3","title":"Safety and Immunogenicity Study of COVID-19 Protein Subunit Recombinant Vaccine","status":"COMPLETED","sponsor":"PT Bio Farma","startDate":"2022-04-13","conditions":["COVID-19"],"enrollment":360,"completionDate":"2023-02-28"},{"nctId":"NCT05651321","phase":"","title":"Studies on the Impact of Taste-aware Intelligent Analysis of Oral Nutritional Supplements","status":"UNKNOWN","sponsor":"Peking Union Medical College Hospital","startDate":"2023-04","conditions":["Cancer- and Cancer Treatment-Related Conditions","Stroke"],"enrollment":108,"completionDate":"2024-12"},{"nctId":"NCT03008122","phase":"PHASE1","title":"Phase I, Randomized, Double-blinded, Placebo-Controlled Dose De-escalation Study to Evaluate Safety and Immunogenicity of Alum Adjuvanted Zika Virus Purified Inactivated Vaccine (ZPIV) in Adults in a Flavivirus Endemic Area","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2017-03-21","conditions":["Zika Virus Infection"],"enrollment":91,"completionDate":"2021-08-10"},{"nctId":"NCT03010228","phase":"PHASE1","title":"Study Assessing the Safety, Immunogenicity and Dose Response of VLA15, A New Vaccine Candidate Against Lyme Borreliosis","status":"COMPLETED","sponsor":"Pfizer","startDate":"2017-01-31","conditions":["Lyme Borreliosis, Nervous System"],"enrollment":179,"completionDate":"2019-01-16"},{"nctId":"NCT05193279","phase":"PHASE2,PHASE3","title":"Safety and Immunogenicity of SCB-2019 in Children <18 Years of Age","status":"WITHDRAWN","sponsor":"Clover Biopharmaceuticals AUS Pty","startDate":"2022-10-05","conditions":["COVID-19"],"enrollment":0,"completionDate":"2022-12-15"},{"nctId":"NCT05012787","phase":"PHASE3","title":"Safety and Immunogenicity of Adjuvanted SARS-CoV-2 (SCB-2019) Vaccine in Adults With Chronic Immune-Mediated Diseases","status":"TERMINATED","sponsor":"Clover Biopharmaceuticals AUS Pty","startDate":"2021-11-12","conditions":["COVID-19"],"enrollment":1,"completionDate":"2022-05-04"},{"nctId":"NCT01011335","phase":"PHASE1,PHASE2","title":"Staphylococcus Aureus Toxoids Phase 1-2 Vaccine Trial","status":"COMPLETED","sponsor":"Henry M. Jackson Foundation for the Advancement of Military Medicine","startDate":"2009-11","conditions":["Staphylococcus Aureus"],"enrollment":176,"completionDate":"2011-03"},{"nctId":"NCT05228613","phase":"PHASE1","title":"Safety and Immunogenicity Study of COVID-19 Protein Subunit Recombinant Vaccine Adjuvanted With Alum+CpG 1018","status":"COMPLETED","sponsor":"PT Bio Farma","startDate":"2022-02-16","conditions":["COVID-19"],"enrollment":175,"completionDate":"2023-01-24"},{"nctId":"NCT05045755","phase":"","title":"The Durability of Protection and Immuno-persistence Study of a Recombinant HPV 16/18 Bivalent Vaccine in Female","status":"UNKNOWN","sponsor":"Jun Zhang","startDate":"2021-04-13","conditions":["Cervical Intraepithelial Neoplasia","Cervical Cancer","Vaginal Intraepithelial Neoplasia","Vulvar Intraepithelial Neoplasia","Persistent Infection"],"enrollment":1339,"completionDate":"2024-01"},{"nctId":"NCT04969445","phase":"","title":"The Durability of Protection Study of a Recombinant HPV 16/18 Bivalent Vaccine in Female","status":"UNKNOWN","sponsor":"Jun Zhang","startDate":"2021-03-30","conditions":["Cervical Intraepithelial Neoplasia","Cervical Cancer","Vaginal Intraepithelial Neoplasia","Vulvar Intraepithelial Neoplasia","Persistent Infection"],"enrollment":647,"completionDate":"2024-01"},{"nctId":"NCT03769194","phase":"PHASE2","title":"Immunogenicity and Safety Study of a Vaccine Against Lyme Borreliosis, in Healthy Adults Aged 18 to 65 Years. Randomized, Controlled, Observer-blind Phase 2 Study.","status":"COMPLETED","sponsor":"Pfizer","startDate":"2018-12-17","conditions":["Lyme Borreliosis"],"enrollment":572,"completionDate":"2020-10-02"},{"nctId":"NCT03345004","phase":"PHASE2","title":"Diamyd Administered Into Lymph Nodes in Combination With Vitamin D in Type 1 Diabetes","status":"COMPLETED","sponsor":"Diamyd Medical AB","startDate":"2017-12-20","conditions":["Diabetes Mellitus, Type 1","Diabetes Mellitus","Autoimmune Diseases","Metabolic Disease","Glucose Metabolism Disorders","Immune System Diseases","Endocrine System Diseases","Juvenile Diabetes","Insulin Dependent Diabetes","Autoimmune Diabetes","Vitamin D","Physiological Effects of Drugs"],"enrollment":109,"completionDate":"2021-04-27"},{"nctId":"NCT05245838","phase":"PHASE1","title":"Trial to Evaluate the Safety, Tolerability, and Immunogenicity of an Investigational Herpes Zoster Vaccine (Z-1018) Compared to Shingrix® in Healthy Adult Volunteers","status":"COMPLETED","sponsor":"Dynavax Technologies Corporation","startDate":"2022-01-10","conditions":["Shingles","Herpes Zoster","Vaccine-Preventable Diseases"],"enrollment":150,"completionDate":"2022-10-20"},{"nctId":"NCT05470803","phase":"PHASE3","title":"An Observer-blind, Cohort Randomized, Exploratory Phase 3 Study to Evaluate the Safety and Immunogenicity of Recombinant Covid-19 Vaccine, mRNA Covid-19 Vaccine and Recombinant SARS-CoV-2 Trimeric S-protein Subunit Vaccine as 4th Dose in Individuals Primed/ Boosted With Various Regimens","status":"UNKNOWN","sponsor":"D'Or Institute for Research and Education","startDate":"2022-08","conditions":["COVID-19"],"enrollment":360,"completionDate":"2023-08"},{"nctId":"NCT04962893","phase":"PHASE2","title":"Study of a Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2) Virus-like Particle (VLP) Vaccine","status":"COMPLETED","sponsor":"Ihsan GURSEL, PhD, Prof.","startDate":"2021-06-26","conditions":["Covid19"],"enrollment":349,"completionDate":"2022-01-16"},{"nctId":"NCT04818281","phase":"PHASE1","title":"Study of a Severe Acute Respiratory Syndrome CoV-2 (SARS-CoV-2) Virus-like Particle (VLP) Vaccine in Healthy Adults","status":"COMPLETED","sponsor":"Ihsan GURSEL, PhD, Prof.","startDate":"2021-03-27","conditions":["Covid19"],"enrollment":38,"completionDate":"2021-12-29"},{"nctId":"NCT02002130","phase":"PHASE1","title":"The Use of Glutamic Acid Decarboxylase (GAD) and Gamma-Amino Butyric Acid (GABA) in the Treatment of Type I Diabetes","status":"COMPLETED","sponsor":"University of Alabama at Birmingham","startDate":"2015-01","conditions":["Type I Diabetes"],"enrollment":101,"completionDate":"2022-04-15"},{"nctId":"NCT04954131","phase":"PHASE2","title":"Immunogenicity and Safety Study of Adjuvanted SARS-CoV-2 (SCB-2019) Vaccine in Adultsin China","status":"UNKNOWN","sponsor":"Zhejiang Clover Biopharmaceuticals, Inc.","startDate":"2021-08-10","conditions":["COVID-19"],"enrollment":766,"completionDate":"2022-11-15"},{"nctId":"NCT05218070","phase":"PHASE1","title":"Safety and Immunogenicity Study of EgyVax Vaccine Candidate for Prophylaxis of COVID-19 Infection","status":"UNKNOWN","sponsor":"Eva Pharma","startDate":"2022-02-06","conditions":["COVID-19"],"enrollment":45,"completionDate":"2023-06"},{"nctId":"NCT04405908","phase":"PHASE1","title":"SCB-2019 as COVID-19 Vaccine","status":"COMPLETED","sponsor":"Clover Biopharmaceuticals AUS Pty","startDate":"2020-06-19","conditions":["COVID-19"],"enrollment":166,"completionDate":"2021-12-08"},{"nctId":"NCT04932824","phase":"PHASE1","title":"Long-term Follow-up to the Phase 1 Study of Adjuvanted SARS-CoV-2 (SCB 2019) Vaccine for COVID-19.","status":"COMPLETED","sponsor":"Clover Biopharmaceuticals AUS Pty","startDate":"2021-01-19","conditions":["COVID-19"],"enrollment":137,"completionDate":"2021-12-16"},{"nctId":"NCT05193734","phase":"PHASE2,PHASE3","title":"Safety and Immunogenicity of 2 Doses Versus 1 Dose of Acellular Pertussis Vaccines Containing Genetically-detoxified Pertussis Toxin in Young Adults Previously Primed With Acellular Pertussis Vaccines","status":"UNKNOWN","sponsor":"University Hospital, Geneva","startDate":"2022-02-07","conditions":["Pertussis","Vaccine-Preventable Diseases"],"enrollment":100,"completionDate":"2023-03-30"},{"nctId":"NCT05128721","phase":"PHASE1","title":"Evaluation of Inactivated Vaccine in Healthy Adults Against Coronavirus Disease of 2019 (COVID-19)","status":"UNKNOWN","sponsor":"National Research Centre, Egypt","startDate":"2021-11-14","conditions":["COVID-19","Vaccine Reaction","Vaccine Adverse Reaction"],"enrollment":72,"completionDate":"2023-05-23"},{"nctId":"NCT00001096","phase":"PHASE1","title":"A Phase I, Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial to Evaluate the Safety and Immunogenicity of HIV-1 MN rsgp120 and Bivalent AIDSVAX B/E (HIV-1 MN rgp120/A244 rgp120) in Combination With QS-21 With or Without Alum in Healthy HIV-1 Uninfected Adults","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"","conditions":["HIV Infections"],"enrollment":60,"completionDate":"2000-03"},{"nctId":"NCT00001031","phase":"PHASE2","title":"A Phase II Clinical Trial to Evaluate the Immunogenicity and Reactogenicity of the Recombinant HIV-1 Envelope Vaccines SF-2 rgp120 (CHO) [Chiron Vaccines] in MF59 Adjuvant and MN rgp120/HIV-1 [VaxGen] in Alum Adjuvant in Healthy Adults","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"","conditions":["HIV Infections"],"enrollment":296,"completionDate":"1997-12"},{"nctId":"NCT00000853","phase":"PHASE1","title":"A Phase I, Multicenter, Randomized, Double-Blind, Placebo-Controlled HIV-1 Vaccine Trial to Evaluate the Safety and Immunogenicity of Low Dose MN rsgp120/HIV-1 (Genentech) in Combination With QS21 Adjuvant or Alum in Healthy Adults","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"","conditions":["HIV Infections"],"enrollment":37,"completionDate":"1999-01"},{"nctId":"NCT00001044","phase":"PHASE1","title":"A Phase I, Multicenter, Randomized, Double-Blind, Placebo-Controlled HIV-1 Vaccine Trial to Evaluate the Safety and Immunogenicity of rgp120/HIV-1MN (Genentech) in Combination With QS21 Adjuvant and/or Alum in Healthy Adults.","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"","conditions":["HIV Infections"],"enrollment":80,"completionDate":"1995-05"},{"nctId":"NCT00001052","phase":"PHASE1","title":"A Phase I, Multicenter, Randomized, Double-Blind, Placebo-Controlled HIV-1 Vaccine Trial to Evaluate the Safety and Immunogenicity of MN Recombinant Soluble gp120/HIV-1 (rsgp120/HIV-1) (Genentech) in Combination With QS21 Adjuvant and/or Alum in Healthy Adults","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"","conditions":["HIV Infections"],"enrollment":110,"completionDate":"1997-09"},{"nctId":"NCT00000809","phase":"PHASE1","title":"Safety and Effectiveness of Two Different Formulations of an HIV Vaccine in Infants Born to HIV-Infected Women","status":"WITHDRAWN","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"","conditions":["HIV Infections","HIV Seronegativity"],"enrollment":0,"completionDate":""},{"nctId":"NCT00000868","phase":"PHASE1","title":"A Study to Evaluate the Safety and Effectiveness of HIV-1 LAI gp120 (an HIV Vaccine) Given With or Without HIV-1 MN rgp120 (Another HIV Vaccine) to HIV-Negative Volunteers","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"","conditions":["HIV Infections","HIV Seronegativity"],"enrollment":27,"completionDate":"2000-05"},{"nctId":"NCT00000866","phase":"NA","title":"A Multicenter, Randomized, Placebo-Controlled, Double-Blind Trial to Evaluate the Safety and Immunogenicity of the Therion Recombinant Vaccinia-HIV-1 IIIB ENV/GAG/POL Vaccine (TCB-3B) and MN RGP 120/HIV-1 In Alum.","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"","conditions":["HIV Infections"],"enrollment":36,"completionDate":"1999-07"},{"nctId":"NCT05087368","phase":"PHASE2","title":"Immunogenicity and Safety of Heterologous and Homologous Boosting With ChAdOx1-S and CoronaVac or a Formulation of SCB-2019 (COVID-19)","status":"UNKNOWN","sponsor":"D'Or Institute for Research and Education","startDate":"2021-12-01","conditions":["Covid19"],"enrollment":520,"completionDate":"2022-04-01"},{"nctId":"NCT00011037","phase":"PHASE2","title":"ALVAC-HIV vCP1452 Alone and Combined With MN rgp120","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"","conditions":["HIV Infections","HIV Seronegativity"],"enrollment":160,"completionDate":"2004-07"},{"nctId":"NCT04950751","phase":"PHASE2","title":"Immunogenicity and Safety of Adjuvanted SCB-2020S Vaccines in Adults","status":"WITHDRAWN","sponsor":"Clover Biopharmaceuticals AUS Pty","startDate":"2021-08","conditions":["COVID-19"],"enrollment":0,"completionDate":"2022-04"},{"nctId":"NCT03783130","phase":"PHASE1","title":"Dose, Safety, Tolerability, and Immunogenicity of an HIV-1 Vaccine, VRC-HIVRGP096-00-VP, With Alum in Healthy Adults","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2019-03-07","conditions":["Human Immunodeficiency Virus Prevention","Human Immunodeficiency Virus (HIV)"],"enrollment":16,"completionDate":"2020-06-24"},{"nctId":"NCT02565511","phase":"PHASE2,PHASE3","title":"A Study of CAD106 and CNP520 Versus Placebo in Participants at Risk for the Onset of Clinical Symptoms of Alzheimer's Disease","status":"TERMINATED","sponsor":"Novartis Pharmaceuticals","startDate":"2015-11-30","conditions":["Alzheimers Disease"],"enrollment":480,"completionDate":"2020-04-30"},{"nctId":"NCT03867331","phase":"PHASE1","title":"To Assess the Safety, Immunogenicity and Efficacy of VLPM01 in Healthy, Malaria-Naïve Volunteers","status":"COMPLETED","sponsor":"VLP Therapeutics","startDate":"2019-03-13","conditions":["Malaria,Falciparum"],"enrollment":36,"completionDate":"2020-05-21"},{"nctId":"NCT02464033","phase":"PHASE2","title":"EDCR Study - Etanercept Diamyd Combination Regimen -Open Trial to Evaluate Safety in Children With Type 1 Diabetes","status":"COMPLETED","sponsor":"Johnny Ludvigsson","startDate":"2015-05","conditions":["Diabetes Mellitus, Type 1"],"enrollment":20,"completionDate":"2019-02-25"},{"nctId":"NCT03141138","phase":"PHASE1","title":"Comparison of Tetravalent Dengue Virus Purified Inactivated Vaccine and Tetravalent Dengue Virus Live Attenuated Vaccine","status":"UNKNOWN","sponsor":"U.S. Army Medical Research and Development Command","startDate":"2017-11-08","conditions":["Dengue Virus"],"enrollment":40,"completionDate":"2021-12-31"},{"nctId":"NCT03879603","phase":"PHASE1","title":"VRC 313: A Trivalent Virus-like Particle (VLP) Encephalitis Vaccine (WEVEE) in Healthy Adults","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2019-04-02","conditions":["Venezuelan Equine Encephalitis","Western Equine Encephalitis","Eastern Equine Encephalitis","Alphavirus Infections"],"enrollment":30,"completionDate":"2020-02-26"},{"nctId":"NCT04641481","phase":"PHASE3","title":"An Efficacy and Safety Clinical Trial of an Investigational COVID-19 Vaccine (BBV152) in Adult Volunteers","status":"UNKNOWN","sponsor":"Bharat Biotech International Limited","startDate":"2020-11-16","conditions":["Covid19","SARS-CoV Infection"],"enrollment":25800,"completionDate":"2022-12"},{"nctId":"NCT01097096","phase":"PHASE2","title":"Safety, Tolerability and Abeta-specific Antibody Response of Repeated i.m. Injections of Adjuvanted CAD106 in Mild Alzheimer Patients","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2010-03","conditions":["Alzheimer's Disease"],"enrollment":177,"completionDate":"2012-12"},{"nctId":"NCT02387164","phase":"PHASE2","title":"Prevention Trial: Immune-tolerance With Alum-GAD (Diamyd) and Vitamin D3 to Children With Multiple Islet Autoantibodies","status":"TERMINATED","sponsor":"Lund University","startDate":"2015-03-09","conditions":["Diabetes Mellitus, Type 1","Prediabetic State"],"enrollment":26,"completionDate":"2019-10-07"},{"nctId":"NCT03049488","phase":"PHASE1","title":"Dose, Safety, Tolerability and Immunogenicity of a Stabilized Prefusion RSV F Subunit Protein Vaccine, VRC-RSVRGP084-00-VP (DS-Cav1), Alone or With Alum Adjuvant, in Healthy Adults","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2017-02-22","conditions":["Respiratory Syncytial Virus"],"enrollment":95,"completionDate":"2019-10-03"},{"nctId":"NCT04478656","phase":"PHASE1","title":"Safety and Immunogenicity of BBV121","status":"COMPLETED","sponsor":"Bharat Biotech International Limited","startDate":"2017-06-03","conditions":["Zika Virus Infection"],"enrollment":48,"completionDate":"2018-11-15"},{"nctId":"NCT03063736","phase":"EARLY_PHASE1","title":"Entolimod, an Adjuvant for Vaccine Augmentation","status":"COMPLETED","sponsor":"Baylor College of Medicine","startDate":"2017-12-08","conditions":["Substance Use Disorders"],"enrollment":40,"completionDate":"2019-12-31"}],"genericFilers":[],"latestUpdates":[],"manufacturing":[],"administration":{"route":"Oral","formulation":"Gel, Spray","formulations":[{"form":"GEL","route":"TOPICAL","productName":"Hand Sanitizer"},{"form":"SPRAY","route":"TOPICAL","productName":"Hand Sanitizer"}]},"crossReferences":{"NUI":"N0000147380","MMSL":"338074","NDDF":"003504","UNII":"1L24V9R23S","VUID":"4019129","CHEBI":"CHEBI:74768","VANDF":"4018332","RXNORM":"221456","UMLSCUI":"C0137988","chemblId":"CHEMBL2107960","DRUGBANK_ID":"DB09087","PUBCHEM_CID":"24856","SNOMEDCT_US":"11036001","MESH_SUPPLEMENTAL_RECORD_UI":"C041524"},"formularyStatus":[],"_enricherVersion":"v2","_offLabelChecked":true,"developmentCodes":[],"ownershipHistory":[{"period":"present","companyName":"Novartis Pharmaceuticals","relationship":"Current Owner"}],"publicationCount":5817,"therapeuticAreas":["Cardiovascular"],"_revenueScrapedAt":"2026-03-31 10:30:20.186205+00","atcClassification":{"source":"DrugCentral","atcCode":"S01XA07","allCodes":["S01XA07"]},"biosimilarFilings":[],"recentPublications":[{"date":"2026 Feb 27","pmid":"41893753","title":"Investigating the In Vitro Immunomodulatory Potential of Microparticulate β-L-Adenosine in Particulate Vaccine Candidates.","journal":"Vaccines"},{"date":"2026 May","pmid":"41887876","title":"Simultaneous removal of fluoride and disinfection by-product precursors through Zr salt enhanced coagulation.","journal":"Journal of environmental sciences (China)"},{"date":"2026 Mar 25","pmid":"41886848","title":"Calcined oyster shell powder as a sustainable alternative to chemical coagulants for enhanced turbidity removal: Optimization of coagulation parameters.","journal":"Journal of environmental management"},{"date":"2026 Mar 21","pmid":"41865485","title":"DNA electroporation of HIV Env elicits robust T cell responses and memory B cell responses with muted serum antibody levels that can be boosted with recombinant protein.","journal":"Vaccine"},{"date":"2026 Mar 12","pmid":"41844084","title":"Two dimensional layered double hydroxides augment antigen loading and release.","journal":"Biomaterials advances"}],"companionDiagnostics":[],"genericManufacturerList":[],"status":"active","companyName":"Novartis Pharmaceuticals","companyId":"novartis","modality":"Biologic","firstApprovalDate":"","aiSummary":"","enrichmentLevel":3,"visitCount":1,"regulatoryByCountry":[{"country_code":"CA","regulator":"Health Canada","status":"approved","approval_date":null,"mah":"","brand_name_local":"","application_number":""},{"country_code":"US","regulator":"FDA","status":"approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null}],"trialStats":{"total":4,"withResults":3},"validation":{"fieldsValidated":0,"lastValidatedAt":"2026-04-20T02:00:02.611326+00:00","fieldsConflicting":1,"overallConfidence":0.8},"verificationStatus":"partial","dataCompleteness":{"mechanism":false,"indications":true,"safety":false,"trials":true,"score":2}}